| 1. |
- Hardcastle, M. J., et al.
(författare)
-
LOFAR/H-ATLAS: a deep low-frequency survey of the Herschel-ATLAS North Galactic Pole field
- 2016
-
Ingår i: Monthly Notices of the Royal Astronomical Society. - : Oxford University Press (OUP). - 0035-8711 .- 1365-2966. ; 462:2, s. 1910-1936
-
Tidskriftsartikel (refereegranskat)abstract
- We present Low-Frequency Array (LOFAR) High-Band Array observations of the Herschel-ATLAS North Galactic Pole survey area. The survey we have carried out, consisting of four pointings covering around 142 deg(2) of sky in the frequency range 126-173 MHz, does not provide uniform noise coverage but otherwise is representative of the quality of data to be expected in the planned LOFAR wide-area surveys, and has been reduced using recently developed 'facet calibration' methods at a resolution approaching the full resolution of the data sets (similar to 10 x 6 arcsec) and an rms off-source noise that ranges from 100 mu Jy beam(-1) in the centre of the best fields to around 2 mJy beam(-1) at the furthest extent of our imaging. We describe the imaging, cataloguing and source identification processes, and present some initial science results based on a 5 sigma source catalogue. These include (i) an initial look at the radio/far-infrared correlation at 150 MHz, showing that many Herschel sources are not yet detected by LOFAR; (ii) number counts at 150 MHz, including, for the first time, observational constraints on the numbers of star-forming galaxies; (iii) the 150-MHz luminosity functions for active and star-forming galaxies, which agree well with determinations at higher frequencies at low redshift, and show strong redshift evolution of the star-forming population; and (iv) some discussion of the implications of our observations for studies of radio galaxy life cycles.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Scott, David R, et al.
(författare)
-
Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom
- 2002
-
Ingår i: Cancer. - : John Wiley and Sons Inc.. - 1097-0142 .- 0008-543X. ; 96:1, s. 14-20
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Human papillomavirus (HPV) DNA testing may be useful in clarifying equivocal cervical cytologic interpretations. One application might be to standardize the meaning of equivocal interpretations from laboratories in various regions. Because international differences may be particularly marked, international comparisons of emerging data will require clear translations of "equivocal" and similar terms. METHODS: To perform a three-country comparison, the authors selected a morphologically diverse set of 188 conventional Papanicolaou tests initially classified as "squamous atypia" from a study of more than 20,000 women in Portland, Oregon (1989-1990). Previously, five U.S. expert cytopathologists independently interpreted the slides with screening cytotechnologists' marks in place. For this comparison, one British and two Scandinavian reviewers involved in HPV research reviewed the slides after original marks had been removed. The authors compared all eight reviewers' classifications of negative, equivocal, or abnormal in a series of pairwise comparisons using the kappa statistic. They then compared cytologic interpretations with HPV DNA testing. RESULTS: Oncogenic HPV DNA detection was significantly associated with increasingly abnormal interpretations for each reader. The British reader tended to rate tests as more abnormal than the American pathologists did, whereas the Scandinavians tended to rate tests as more normal. Reference to the HPV DNA standard clarified the tendency of readers to render systematically more or less severe interpretations. For example, the Scandinavian cytologists discounted subtle (often HPV-associated) changes in favor of cytologic certainty, making HPV triage of equivocal tests less applicable there. CONCLUSIONS: International research on cytopathology, particularly on the possible uses of HPV DNA testing, will require calibration of local cytologic definitions.
|
|
| 5. |
- Stanley, Flora, 1990, et al.
(författare)
-
The mean star formation rates of unobscured QSOs: searching for evidence of suppressed or enhanced star formation
- 2017
-
Ingår i: Monthly Notices of the Royal Astronomical Society. - : Oxford University Press (OUP). - 0035-8711 .- 1365-2966. ; 472:2, s. 2221-2240
-
Tidskriftsartikel (refereegranskat)abstract
- We investigate the mean star formation rates (SFRs) in the host galaxies of similar to 3000 optically selected quasi-stellar objects (QSOs) from the Sloan Digital Sky Survey within the Herschel-ATLAS fields, and a radio-luminous subsample covering the redshift range of z = 0.2-2.5. Using Wide-field Infrared Survey Explorer (WISE) and Herschel photometry (12-500 mu m) we construct composite spectral energy distributions (SEDs) in bins of redshift and active galactic nucleus (AGN) luminosity. We perform SED fitting to measure the mean infrared luminosity due to star formation, removing the contamination from AGN emission. We find that the mean SFRs show a weak positive trend with increasing AGN luminosity. However, we demonstrate that the observed trend could be due to an increase in black hole (BH) mass (and a consequent increase of inferred stellar mass) with increasing AGN luminosity. We compare to a sample of X-ray selected AGN and find that the two populations have consistent mean SFRs when matched in AGN luminosity and redshift. On the basis of the available virial BH masses, and the evolving BH mass to stellar mass relationship, we find that the mean SFRs of our QSO sample are consistent with those of main sequence star-forming galaxies. Similarly the radio-luminous QSOs have mean SFRs that are consistent with both the overall QSO sample and with star-forming galaxies on the main sequence. In conclusion, on average QSOs reside on the main sequence of star-forming galaxies, and the observed positive trend between the mean SFRs and AGN luminosity can be attributed to BH mass and redshift dependencies.
|
|
| 6. |
- Stojkov, K, et al.
(författare)
-
Guideline-based indicators for adult patients with myelodysplastic syndromes
- 2020
-
Ingår i: Blood advances. - : American Society of Hematology. - 2473-9537 .- 2473-9529. ; 4:16, s. 4029-4044
-
Tidskriftsartikel (refereegranskat)abstract
- Myelodysplastic syndromes (MDSs) represent a heterogeneous group of hematological stem cell disorders with an increasing burden on health care systems. Evidence-based MDS guidelines and recommendations (G/Rs) are published but do not necessarily translate into better quality of care if adherence is not maintained in daily clinical practice. Guideline-based indicators (GBIs) are measurable elements for the standardized assessment of quality of care and, thus far, have not been developed for adult MDS patients. To this end, we screened relevant G/Rs published between 1999 and 2018 and aggregated all available information as candidate GBIs into a formalized handbook as the basis for the subsequent consensus rating procedure. An international multidisciplinary expert panel group (EPG) of acknowledged MDS experts (n = 17), health professionals (n = 7), and patient advocates (n = 5) was appointed. The EPG feedback rates for the first and second round were 82% (23 of 28) and 96% (26 of 27), respectively. A final set of 29 GBIs for the 3 domains of diagnosis (n = 14), therapy (n = 8), and provider/infrastructural characteristics (n = 7) achieved the predefined agreement score for selection (>70%). We identified shortcomings in standardization of patient-reported outcomes, toxicity, and geriatric assessments that need to be optimized in the future. Our GBIs represent the first comprehensive consensus on measurable elements addressing best practice performance, outcomes, and structural resources. They can be used as a standardized instrument with the goal of assessing, comparing, and fostering good quality of care within clinical development cycles in the daily care of adult MDS patients.
|
|
| 7. |
- Arnold, S. V., et al.
(författare)
-
Recognition of Incident Diabetes Mellitus During an Acute Myocardial Infarction
- 2015
-
Ingår i: Circulation-Cardiovascular Quality and Outcomes. - : Ovid Technologies (Wolters Kluwer Health). - 1941-7705 .- 1941-7713. ; 8:3, s. 260-267
-
Tidskriftsartikel (refereegranskat)abstract
- Background-Diabetes mellitus (DM) is common in patients hospitalized with an acute myocardial infarction (AMI), representing in some cases the first opportunity to recognize and treat DM. We report the incidence of new DM and its recognition among patients with AMI. Methods and Results-Patients in a 24-site US AMI registry (2005-08) had glycosylated hemoglobin assessed at a core laboratory, with results blinded to clinicians and local clinical measurements left to the discretion of the treating providers. Among 2854 AMI patients without known DM on admission, 287 patients (10%) met criteria for previously unknown DM, defined by a core laboratory glycosylated hemoglobin of >= 6.5%. Among these, 186 (65%) were unrecognized by treating clinicians, receiving neither DM education, glucose-lowering medications at discharge, nor documentation of DM in the chart (median glycosylated hemoglobin of unrecognized patients, 6.7%; range, 6.5-12.3%). Six months after discharge, only 5% of those not recognized as having DM during hospitalization had been initiated on glucose-lowering medications versus 66% of those recognized (P< 0.001). Conclusions-Underlying DM that has not been previously diagnosed is common among AMI patients, affecting 1 in 10 patients, yet is recognized by the care team only one third of the time. Given its frequency and therapeutic implications, including but extending beyond the initiation of glucose-lowering treatment, consideration should be given to screening all AMI patients for DM during hospitalization. Inexpensive, ubiquitous, and endorsed as an acceptable screen for DM, glycosylated hemoglobin testing should be considered for this purpose.
|
|
| 8. |
- Bacon, David J., et al.
(författare)
-
Cosmology with Phase 1 of the Square Kilometre Array Red Book 2018 : Technical specifications and performance forecasts
- 2020
-
Ingår i: Publications Astronomical Society of Australia. - : Cambridge University Press (CUP). - 1323-3580 .- 1448-6083. ; 37
-
Tidskriftsartikel (refereegranskat)abstract
- We present a detailed overview of the cosmological surveys that we aim to carry out with Phase 1 of the Square Kilometre Array (SKA1) and the science that they will enable. We highlight three main surveys: a medium-deep continuum weak lensing and low-redshift spectroscopic HI galaxy survey over 5 000 deg2; a wide and deep continuum galaxy and HI intensity mapping (IM) survey over 20 000 deg2 from z = 0.35 to 3; and a deep, high-redshift HI IM survey over 100 deg2 from z = 3 to 6. Taken together, these surveys will achieve an array of important scientific goals: measuring the equation of state of dark energy out to z = 3 with percent-level precision measurements of the cosmic expansion rate; constraining possible deviations from General Relativity on cosmological scales by measuring the growth rate of structure through multiple independent methods; mapping the structure of the Universe on the largest accessible scales, thus constraining fundamental properties such as isotropy, homogeneity, and non-Gaussianity; and measuring the HI density and bias out to z = 6. These surveys will also provide highly complementary clustering and weak lensing measurements that have independent systematic uncertainties to those of optical and near-infrared (NIR) surveys like Euclid, LSST, and WFIRST leading to a multitude of synergies that can improve constraints significantly beyond what optical or radio surveys can achieve on their own. This document, the 2018 Red Book, provides reference technical specifications, cosmological parameter forecasts, and an overview of relevant systematic effects for the three key surveys and will be regularly updated by the Cosmology Science Working Group in the run up to start of operations and the Key Science Programme of SKA1.
|
|
| 9. |
- Jarvis, M.J., et al.
(författare)
-
The discovery of a z = 0.7092 OH megamaser with the MIGHTEE survey
- 2024
-
Ingår i: Monthly Notices of the Royal Astronomical Society. - 0035-8711 .- 1365-2966. ; 529:4, s. 3484-3494
-
Tidskriftsartikel (refereegranskat)abstract
- We present the discovery of the most distant OH megamaser (OHM) to be observed in the main lines, using data from the MeerKAT International Giga-Hertz Tiered Extragalactic Exploration (MIGHTEE) survey. At a newly measured redshift of z = 0.7092, the system has strong emission in both the 1665 MHz (L ≈ 2500 L-) and 1667 MHz (L ≈ 4.5 × 104 L-) transitions, with both narrow and broad components. We interpret the broad line as a high-velocity-dispersion component of the 1667 MHz transition, with velocity v ∼330 km s-1 with respect to the systemic velocity. The host galaxy has a stellar mass of M = 2.95 × 1010 M- and a star formation rate of SFR = 371 M- yr-1, placing it ∼1.5 dex above the main sequence for star-forming galaxies at this redshift, and can be classified as an ultraluminous infrared galaxy. Alongside the optical imaging data, which exhibit evidence for a tidal tail, this suggests that the OHM arises from a system that is currently undergoing a merger, which is stimulating star formation and providing the necessary conditions for pumping the OH molecule to saturation. The OHM is likely to be lensed, with a magnification factor of ∼2.5, and perhaps more if the maser emitting region is compact and suitably offset relative to the centroid of its host galaxy's optical light. This discovery demonstrates that spectral line mapping with the new generation of radio interferometers may provide important information on the cosmic merger history of galaxies.
|
|
| 10. |
- Welsh, Joshua A., et al.
(författare)
-
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
- 2024
-
Ingår i: Journal of Extracellular Vesicles. - : John Wiley and Sons Inc. - 2001-3078. ; 13:2
-
Tidskriftsartikel (refereegranskat)abstract
- Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells. These features indicate strong biomarker and therapeutic potential and have generated broad interest, as evidenced by the steady year-on-year increase in the numbers of scientific publications about EVs. Important advances have been made in EV metrology and in understanding and applying EV biology. However, hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non-vesicular extracellular particles, characterisation and functional studies. To address the challenges and opportunities in this rapidly evolving field, the International Society for Extracellular Vesicles (ISEV) updates its ‘Minimal Information for Studies of Extracellular Vesicles’, which was first published in 2014 and then in 2018 as MISEV2014 and MISEV2018, respectively. The goal of the current document, MISEV2023, is to provide researchers with an updated snapshot of available approaches and their advantages and limitations for production, separation and characterisation of EVs from multiple sources, including cell culture, body fluids and solid tissues. In addition to presenting the latest state of the art in basic principles of EV research, this document also covers advanced techniques and approaches that are currently expanding the boundaries of the field. MISEV2023 also includes new sections on EV release and uptake and a brief discussion of in vivo approaches to study EVs. Compiling feedback from ISEV expert task forces and more than 1000 researchers, this document conveys the current state of EV research to facilitate robust scientific discoveries and move the field forward even more rapidly.
|
|
